Vor Biopharma
48 hedge funds and large institutions have $125M invested in Vor Biopharma in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 9 closing their positions.
55% more call options, than puts
Call options by funds: $31K | Put options by funds: $20K
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more ownership
Funds ownership: 4.14% → 4.14% (+0%)
2% less funds holding
Funds holding: 49 → 48 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
17% less capital invested
Capital invested by funds: $151M → $125M (-$25.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$1.96M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$1.61M |
| 3 |
ABG
Ally Bridge Group
New York
|
+$1.25M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.03M |
| 5 |
Millennium Management
New York
|
+$246K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.55M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$280K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$264K |
| 4 |
JP Morgan Chase
New York
|
-$208K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$150K |
VOR Hedge Fund Activity: Q3 2022 in Review
48 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q3 2022, worth a combined $125M — down 17% from $151M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VOR and 8 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 13 added.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $1.96M. The largest seller was OrbiMed, cutting an estimated $3.55M.
- 48 institutional investors held Vor Biopharma (VOR) as of Q3 2022, down from 49 in Q2 2022.
- Funds reported $125M of Vor Biopharma stock for Q3 2022, down 17% quarter-over-quarter.
- 8 funds opened new Vor Biopharma positions in Q3 2022 and 9 closed out, a net change of -1 holder.
- The largest Vor Biopharma buyer in Q3 2022 was Paradigm Biocapital Advisors, an estimated $1.96M added.
- The largest Vor Biopharma seller in Q3 2022 was OrbiMed, an estimated $3.55M sold.
Based on aggregated 13F filings for Q3 2022.